Abstract

A range of novel lipid‐lowering agents are now available, providing options for patients unable to achieve sufficient control on older drugs such as statins. This article gives an overview of the main lipid‐lowering agents, their indications and usage, with a focus on the newer therapies targeting PCSK9.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call